Skip to main content

Table 3 Multivariable Cox proportional hazards model for mortality (n = 118)

From: Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study

 

Transplant-censored

Competing analysis

Model 1

Hazard ratio

95%CI

p value

Hazard ratio

95%CI

P value

Radiological PPFE

0.51

(0.25, 1.05)

0.07

0.57

(0.30, 1.12)

0.10

Age

1.04

(1.01, 1.07)

0.01

1.03

(1.01, 1.06)

0.02

Male

1.05

(0.61, 1.82)

0.86

0.88

(0.51, 1.52)

0.65

%FVC

0.97

(0.95, 1.00)

0.03

0.98

(0.96, 1.00)

0.07

Six-minute walk distance < 250 m

1.87

(1.02, 3.43)

0.04

2.36

(1.33, 4.19)

0.003

Model 2

Category

 Fibrotic ILDsa without radiological PPFE

Ref.

–

–

Ref.

–

–

 Idiopathic PPFE and LONIPC with radiological PPFE

0.38

(0.16, 0.90)

0.03

0.41

(0.21, 0.80)

0.01

 Other fibrotic ILDs with radiological PPFE

0.96

(0.35, 2.64)

0.94

1.19

(0.51, 2.78)

0.69

Age

1.03

(1.00, 1.07)

0.02

1.03

(1.00, 1.06)

0.04

Male

1.01

(0.58, 1.75)

0.98

0.85

(0.49, 1.47)

0.56

%FVC

0.98

(0.95, 1.00)

0.03

0.98

(0.97, 1.00)

0.06

Six-minute walk distance < 250 m

1.99

(1.07, 3.70)

0.03

2.51

(1.39, 4.54)

0.002

Model 3

Category

 Fibrotic ILDs without radiological PPFE

Ref.

–

–

Ref.

–

–

 Idiopathic PPFE

0.35

(0.12, 1.04)

0.06

0.39

(0.20, 0.78)

0.01

 LONIPC with radiological PPFE

0.42

(0.12, 1.50)

0.18

0.43

(0.35, 2.64)

0.15

 Other fibrotic ILDsa with radiological PPFE

0.96

(0.35, 2.64)

0.94

1.19

(0.51, 2.78)

0.69

Age

1.04

(1.00, 1.07)

0.02

1.03

(1.00, 1.07)

0.04

Male

1.01

(0.58, 1.75)

0.98

0.85

(0.58, 1.75)

0.57

%FVC

0.98

(0.95, 1.00)

0.03

0.98

(0.95, 1.00)

0.06

Six-minute walk distance < 250 m

2.00

(1.07, 3.74)

0.03

2.52

(1.39, 4.54)

0.003

  1. aOther fibrotic ILDs are IPF, other IIPs, CTD-ILD, and HP
  2. Abbreviations: ILD interstitial lung disease, PPFE plueroparenchymal fibroelastosis, LONIPC late-onset non-infectious pulmonary complication after hematopoetic stem-cell transplantation and/or chemotherapy, %FVC the percentage to predicted forced vital capacity, IPF idiopathic pulmonary fibrosis, other IIPs other idiopathic interstitial pneumonias than idiopathic pulmonary fibrosis, CTD-ILD connective tissue disease-associated interstitial lung disease, HP hypersensitivity pneumonia